Advertisement
Advertisement

VYGR

VYGR logo

Voyager Therapeutics, Inc. Common Stock

3.05
USD
Sponsored
-0.05
-1.58%
Jul 27, 13:46 UTC -4
Open

VYGR Earnings Reports

Positive Surprise Ratio

VYGR beat 26 of 42 last estimates.

62%

Next Report

In 3 Days
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$4.82M
/
-$0.49
Implied change from Q1 26 (Revenue/ EPS)
+85.98%
/
+4.26%
Implied change from Q2 25 (Revenue/ EPS)
-7.26%
/
-12.50%

Voyager Therapeutics, Inc. Common Stock earnings per share and revenue

On May 07, 2026, VYGR reported earnings of -0.47 USD per share (EPS) for Q1 26, beating the estimate of -0.56 USD, resulting in a 16.40% surprise. Revenue reached 2.59 million, compared to an expected 8.96 million, with a -71.06% difference. The market reacted with a +2.27% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 4.82 million USD, implying an increase of 4.26% EPS, and increase of 85.98% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
logo
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
logo
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
logo
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
For Q1 2026, Voyager Therapeutics, Inc. Common Stock reported EPS of -$0.47, beating estimates by 16.4%, and revenue of $2.59M, -71.06% below expectations.
The stock price moved up 2.27%, changed from $3.96 before the earnings release to $4.05 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 10 analysts, Voyager Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $4.82M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement